Georgia is currently home to 1922 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant
NCT05948540
Recruiting
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Intervention C - Daridorexant will assess the safety and efficacy of daridorexant in participants with PTSD. Please see NCT05422612 for information on the S-21-02 Master Protocol.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/27/2025
Locations: Advanced Discovery Research, Atlanta, Georgia
Conditions: Post Traumatic Stress Disorder
Register for Updates
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
NCT05946941
Recruiting
The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Augusta University, Augusta, Georgia
Conditions: Sjögren's Syndrome
Register for Updates
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: The Emory Clinic, Atlanta, Georgia
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/27/2025
Locations: Emory Brain Health Center, Atlanta, Georgia
Conditions: Primary Generalized Tonic-Clonic Seizures
Register for Updates
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114
Recruiting
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
06/27/2025
Locations: Parris and Associates Rheumatology, Lawrenceville, Georgia
Conditions: Systemic Lupus Erythematosus
Register for Updates
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749
Recruiting
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
06/27/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Systemic Lupus Erythematosus
Register for Updates
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063
Recruiting
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Emory Brain Health Center, Atlanta, Georgia
Conditions: Focal Onset Seizures
Register for Updates
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
NCT05554406
Recruiting
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to t... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
06/27/2025
Locations: Augusta University Medical Center, Augusta, Georgia
Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Register for Updates
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
NCT05536141
Recruiting
The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab in participants with ccRCC in the dose expansion stage
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Clear Cell Renal Cell Carcinoma, Solid Tumors
Register for Updates
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
NCT05429632
Recruiting
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/27/2025
Locations: Emory University - Winship Cancer Institute (WCI), Atlanta, Georgia
Conditions: Adult Acute Myeloid Leukemia
Register for Updates
Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder
NCT05423717
Recruiting
This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to \< 18 years with insomnia disorder.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
06/27/2025
Locations: NeuroTrials Research, Inc., Atlanta, Georgia
Conditions: Insomnia
Register for Updates
Department of Defense PTSD Adaptive Platform Trial - Master Protocol
NCT05422612
Recruiting
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Participants are randomized among the multiple cohorts in the study and the resulting randomization enables sharing/pooling of control participants, where all interventions may be compared to a common control (placebo). This master protocol describes the default procedures and analyses for all cohorts;... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/27/2025
Locations: Advanced Discovery Research, Atlanta, Georgia
Conditions: Post Traumatic Stress Disorder
Register for Updates